The Conversation (0)
Corbus Pharmaceuticals Holdings presented the safety and efficacy data from its completed Phase 2 clinical study of anabasum at the European League Against Rheumatism Annual Meeting.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) presented the safety and efficacy data from its completed Phase 2 clinical study of anabasum at the European League Against Rheumatism Annual Meeting.
As quoted in the press release:
The presentation included a review of the Phase 2 topline data previously announced, additional data from the study regarding Patient-Reported Outcomes Measurement Information System (PROMIS)-29, and additional analysis of the previously-reported CRISS domains and transcriptome data.
The abstract titled, “A Phase 2 study safety and efficacy of anabasum (JBT-101) in systemic sclerosis,” was presented by Robert Spiera, M.D., Director of the Vasculitis and Scleroderma Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City, and Principle Investigator of Corbus’ Phase 2 systemic sclerosis clinical study. To view the presentation, please click here.
Anabasum was granted Orphan Drug Designation and Fast Track status for the treatment of systemic sclerosis from the FDA in 2015 and Orphan Designation from the EMA in January 2017. Corbus also has an ongoing 12-month, open-label extension to its Phase 2 clinical study of anabasum for systemic sclerosis and expects to report data from this study in the fourth quarter of 2017.
Click here to read the full press release.
Source: www.marketwired.com
